Vistagen Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Vistagen Therapeutics wird ein Gewinn- und Umsatzwachstum von 9.5% bzw. 60.1% pro Jahr prognostiziert, während der Gewinn pro Aktie um 17.1% pro Jahr wachsen soll.

Wichtige Informationen

9.5%

Wachstumsrate der Gewinne

17.1%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	27.3%
Wachstumsrate der Einnahmen	60.1%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	08 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

VistaGen to proceed with phase 3 anxiety nasal spray trial following interim analysis

Sep 08

VistaGen drops 80% as late-stage study for anxiety therapy fails

Jul 22

Here's Why We're Not Too Worried About VistaGen Therapeutics' (NASDAQ:VTGN) Cash Burn Situation

Apr 10

VistaGen Therapeutics added to Russell 2000 Index

Jun 16

VistaGen Therapeutics (NASDAQ:VTGN) Is In A Strong Position To Grow Its Business

Jun 07

VistaGen Therapeutics slumps in after hours trade on underwritten public offering

Dec 17

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:VTGN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2027	5	-90	-104	-103	3
3/31/2026	0	-79	-68	-67	4
3/31/2025	1	-57	-51	-50	4
9/30/2024	1	-40	-34	-33	N/A
6/30/2024	1	-33	-29	-29	N/A
3/31/2024	1	-29	-26	-26	N/A
12/31/2023	1	-32	-26	-26	N/A
9/30/2023	1	-35	-31	-31	N/A
6/30/2023	0	-46	-42	-42	N/A
3/31/2023	0	-59	-50	-50	N/A
12/31/2022	0	-64	-58	-58	N/A
9/30/2022	0	-65	-60	-60	N/A
6/30/2022	1	-60	-55	-55	N/A
3/31/2022	1	-49	-45	-45	N/A
12/31/2021	2	-62	-35	-35	N/A
9/30/2021	1	-56	-28	-28	N/A
6/30/2021	1	-47	-16	-15	N/A
3/31/2021	1	-42	-12	-12	N/A
12/31/2020	1	-16	-10	-9	N/A
9/30/2020	0	-17	-9	-9	N/A
6/30/2020	N/A	-19	-14	-14	N/A
3/31/2020	N/A	-22	-16	-16	N/A
12/31/2019	N/A	-24	-17	-17	N/A
9/30/2019	N/A	-26	-16	-16	N/A
6/30/2019	N/A	-28	-16	-16	N/A
3/31/2019	N/A	-26	-15	-15	N/A
12/31/2018	N/A	-24	-14	-14	N/A
9/30/2018	N/A	-20	-12	-12	N/A
6/30/2018	N/A	-18	N/A	-10	N/A
3/31/2018	N/A	-16	N/A	-9	N/A
12/31/2017	N/A	-14	N/A	-8	N/A
9/30/2017	1	-13	N/A	-7	N/A
6/30/2017	1	-12	N/A	-8	N/A
3/31/2017	1	-12	N/A	-7	N/A
12/31/2016	1	-18	N/A	-7	N/A
9/30/2016	N/A	-19	N/A	-6	N/A
6/30/2016	N/A	-24	N/A	-6	N/A
3/31/2016	N/A	-51	N/A	-5	N/A
12/31/2015	N/A	-48	N/A	-4	N/A
9/30/2015	N/A	-46	N/A	-4	N/A
6/30/2015	N/A	-39	N/A	-3	N/A
3/31/2015	N/A	-14	N/A	-3	N/A
12/31/2014	N/A	-9	N/A	-2	N/A
9/30/2014	N/A	-8	N/A	-2	N/A
6/30/2014	N/A	-8	N/A	-2	N/A
3/31/2014	N/A	-3	N/A	-2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: VTGN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: VTGN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: VTGN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: VTGNDie Einnahmen des Unternehmens (60.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: VTGNDie Einnahmen des Unternehmens (60.1% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von VTGN in 3 Jahren voraussichtlich hoch sein wird

Vistagen Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates increase by 161%

Consensus EPS estimates upgraded to US$1.60 loss, revenue downgraded

Forecast to breakeven in 2026

Price target decreased to US$2.82

Consensus forecasts updated

Forecast to breakeven in 2025

Recent updates

Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Vistagen to Present At the 2024 Neuroscience Education Institute Congress

Vistagen Therapeutics, Inc. to Report Q2, 2025 Results on Nov 07, 2024

Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Consensus revenue estimates increase by 161%

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Vistagen Therapeutics, Inc. to Report Q1, 2025 Results on Aug 13, 2024

Full year 2024 earnings: EPS exceeds analyst expectations

New minor risk - Market cap size

Vistagen Therapeutics, Inc. to Present At the 2024 American Society of Clinical Psychopharmacology Conference

Vistagen Announces Positive Results from Phase 2A Pilot Study of Ph15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue

Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2

Consensus EPS estimates upgraded to US$1.60 loss, revenue downgraded

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Vistagen Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Vistagen Therapeutics, Inc. to Report Q3, 2024 Results on Feb 13, 2024

Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain

Vistagen Therapeutics, Inc. to Report Q2, 2024 Results on Nov 09, 2023

Vistagen Therapeutics, Inc. Appoints Joshua Prince as the Chief Operating Officer

New major risk - Shareholder dilution

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder

Vistagen Appoints Cindy Anderson as Chief Financial Officer

Vistagen Therapeutics, Inc. Announces Positive Phase 3 Trial Results from Phase 3 Palisade-2 Trial of Rapid-onset Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder (SAD)

Vistagen Therapeutics, Inc. to Report Q1, 2024 Results on Aug 10, 2023

New major risk - Share price stability

Vistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder

Vistagen Therapeutics, Inc., Annual General Meeting, Sep 25, 2023

Vistagen Therapeutics, Inc. Announces New Mechanism of Action Data from Preclinical Tissue Distribution Study in Laboratory Rats

Vistagen Therapeutics, Inc. Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Spray's Potential Antidepressant Activity Via Peripheral Nasal Neurons Without Entry into the Brain

Vistagen Therapeutics, Inc. Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease

Vistagen Therapeutics, Inc. Announces Retirement of Jerrold D. Dotson, Chief Financial Officer, Effective on or About August 31, 2023

Vistagen Regains Full Compliance with Nasdaq Listing Requirements

Vistagen Announces Results of Successful U.S. Phase 1 Study of Itruvone (PH10), Enabling U.S. Phase 2B Development for Treatment of Major Depressive Disorder

Vistagen Announces European Patent Office Intention to Grant New PH80 Nasal Spray Patent for the Treatment of Migraine

VistaGen Therapeutics, Inc. Announces Positive Results from Exploratory Phase 2A Study of PH80 in Women Diagnosed with Menopausal Hot Flashes

Vistagen Provides Nasdaq Compliance Update

Forecast to breakeven in 2026

VistaGen Therapeutics, Inc. to Report Q3, 2023 Results on Feb 07, 2023

VistaGen Therapeutics, Inc. (NasdaqCM:VTGN) completed the acquisition of Pherin Pharmaceuticals, Inc.

Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder

Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety

Vistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive Disorder

Vistagen Receives FDA "Study May Proceed" Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder

VistaGen Therapeutics, Inc. Announces Publication in Cells Demonstrating AV-101’s Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease

Price target decreased to US$2.82

VistaGen Therapeutics, Inc. to Report Q2, 2023 Results on Nov 10, 2022

VistaGen Therapeutics, Inc., Annual General Meeting, Oct 28, 2022

Vistagen Presents Poster at Psych Congress 2022 Highlighting Effect of PH94B on Nasal Electrogram Responses and Biomarkers of Autonomic Nervous System Activity in Healthy Human Subjects

Vistagen Therapeutics, Inc. Announces Completion of an Interim Analysis of PALISADE-2

VistaGen to proceed with phase 3 anxiety nasal spray trial following interim analysis

Vistagen Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance of Minimum Bid Price

VistaGen Therapeutics, Inc., Annual General Meeting, Oct 14, 2022

CEO & Director recently bought US$103k worth of stock

Consensus forecasts updated

Forecast to breakeven in 2025

Consensus forecasts updated

Price target decreased to US$3.36

Vistagen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for Investigational Drug Ph94b

VistaGen drops 80% as late-stage study for anxiety therapy fails

Consensus revenue estimates fall by 32%

No longer forecast to breakeven

VistaGen Therapeutics, Inc. Terminates Employment of H. Ralph Snodgrass as President and Chief Scientific Officer

VistaGen Therapeutics, Inc. to Report Fiscal Year 2022 Results on Jun 23, 2022

CEO & Director exercised options to buy US$120k worth of stock.

VistaGen Announces Key Regulatory Update on Ph94b for the Acute Treatment of Social Anxiety Disorder

VistaGen Therapeutics, Inc. Appoints Reid Adler as Chief Legal Officer

Forecast to breakeven in 2025

VistaGen Therapeutics, Inc. to Present Preclinical Data on Lead Candidate PH94B At Upcoming Scientific Congresses

Forecast to breakeven in 2025